A priest, president of Human Life International (HLI) based in Maryland, has asked Congress to investigate reports of women in some developing countries unknowingly receiving a tetanus vaccine laced with the anti-fertility drug human chorionic gonadotropin (hCG).
UNICEF, which also says it's seen the results, added another note of caution, arguing that the labs testing the samples for the Catholic groups were not informed that they were testing a vaccine and used "analyzers used for testing human samples like blood and urine for pregnancy" to look for the presence of the hormone, which happens to be the very same one detected by pregnancy tests.
In 1993, WHO announced a “birth-control vaccine” for “family planning”. Published research shows that by 1976 WHO researchers had conjugated tetanus toxoid (TT) with human chorionic gonadotropin (hCG) producing a “birth-control” vaccine. Conjugating TT with hCG causes pregnancy hormones to be attacked by the immune system. Expected results are abortions in females already pregnant and/or infertility in recipients not yet impregnated. Repeated inoculations prolong infertility. Currently WHO researchers are working on more potent anti-fertility vaccines using recombinant DNA. WHO publications show a long-range purpose to reduce population growth in unstable “less developed countries”.
The type of anti-tetanus “birth-control” vaccine the KCCB and KCDA suspected the WHO of using in Kenya involves the linking the beta portion of the hCG hormone with the active agent in tetanus vaccines which is tetanus toxoid (TT). In fact, WHO biomedical researchers have been working to engineer such an “anti-fertility” vaccine for “birth-control” at least since 1972. Research published in 1976 confirmed that recipients of a vaccine containing βhCG chemically conjugated with TT develop antibodies not only against TT but also against βhCG. The result, first reported by WHO researchers at a meeting of the US National Academy of Sciences [5] , is a “birth-control” vaccine that diminishes the βhCG essential to a successful pregnancy and causes at least temporary “infertility”. Subsequent research showed that repeated doses can extend infertility indefinitely [6] [8] [10] [11] [13] [14] [23] [24] [26] [50] . In the reported clinical trials [10] [13] [14] , researchers systematically avoided administering an “anti-fertility” vaccine to a pregnant woman on the theory that it would cause an abortion as it does in experimental animal models [26] .
HCG IS PRODUCED mainly by the syncytiotrophoblast cells of the periimplantation embryo and, to a lesser extent, by the pituitary gland and is a heterodimer composed of a noncovalently linked α-subunit (hCGα) and a β-subunit (hCGβ). It is structurally related to the pituitary hormones FSH, LH, and TSH, with a common α-subunit and a specific β-subunit. hCG is considered to play an essential role in the establishment and maintenance of early pregnancy.
hCG antibodies have been found under a number of circumstances. 1) Vaccination against hCG has been shown to block fertility in the marmoset, the baboon, and the rhesus monkey (1). In addition, clinical trials have demonstrated that immunization of women with either hCGβ, a heterospecies dimer of hCGβ associated with the α-subunit of ovine LH, or the C-terminal region of hCGβ resulted in the development of contraceptive levels of anti-hCG antibodies (2–4). The study of Talwar et al. (3) also provided evidence that the circulating anti-hCG antibodies prevented pregnancy in 1224 cycles, and that booster injections were required to maintain antibody titers. Fertility was restored when titers (neutralization capacity of the antibody) dropped below 35 ng hCG/ml of serum. 2) hCG antibodies have been detected in young males who had been treated with exogenous urinary hCG (5, 6). 3) The presence of naturally occurring antibodies to hCG/LH has also been reported in young women. Wass et al. (7) described the presence of antibodies to hCG/LH in normal sera, but these affinities were too low to affect biological activity. Subsequently, a woman has been reported with a history of spontaneous abortion, followed by an anovular period and then normal ovulatory cycles and variations in hCG/LH titers in her serum (8). The patient had no previous exposure to hormone therapy.
Abstract
Vaccines are under development for the control of fertility in males and females. This review discusses developments in anti-fertility vaccines at the National Institute of Immunology, New Delhi, India. A single injection procedure for the sterilization or castration of male animals depending on the site at which the injection is given, has passed through field testing and is expected to be on the market in the near future. Vaccines inducing antibodies against the human chorionic gonadotropin have gone through phase I trials with satisfactory results. A vaccine producing a consistently bioeffective antibody response against gonadotropin-releasing hormone is ready for phase I/II clinical trials in patients of carcinoma of prostate after due experimentation in animals and toxicology studies. Research to identify sperm antigens for incorporation into second generation vaccines is in progress.
PIP: Anti-fertility vaccine research carried out at the National Institute of Immunology in New Delhi, India is summarized. The vaccines react against follicle stimulating hormone (FSH), luteinizing hormone (LH), and gonadotropin releasing hormone (GnRH). Intratesticular injection of Bacillus Calmette-Guerin (BCG) in moderate concentrations causes the degeneration of the blood-testes barrier, which finally leads to reversible azoospermia and it is suited for use in animals. Anti-hCG (anti-human chorionic gonadotropin) vaccines include beta-hCG linked to tetanus toxoid /TT (beta-hCG-TT) the alpha-subunit of ovine LH associated with beta-hCG and linked to TT or cholera toxin chain b (CHB/alpha-oLH, beta-hCG-TT/CHB/, the mixture of hCG and oLH, and 37 amino acid carboxy-terminal peptide (CTP) of beta-hCG linked to diphtheria toxoid (DT). The principle of anti-hCG vaccine is to induce antibodies which can bind to hCG and render it biologically inactive. The beta-subunit of hCG has proven efficacious in controlling fertility, and similarly 36 amino acid CTP was effective in baboons. The beta-hCG- TT vaccine evoked the production of anti-hCG antibodies in 61 of 63 women tested. The mixture of beta-hCG and beta-ovine LH conjugated to TT or CHB /formulation M/ and beta-hCG annealed to alpha-ovine LH and conjugated to TT or to CHB (formulation A/ produced improved) immunogenicity. Immunization with GnRH resulted in decreased testicular size, drop of testosterone levels, and marked atrophy of the prostate. Anti-GnRH vaccine would be tried in patients of carcinoma of the prostate. LDH-C4, a sperm-specific mitochondrial antigen, produced an antibody response in baboons and reduced fertility in the females. Animal fertility control vaccines will be shortly on the market, but the use of recombinant DNA techniques should also accelerate the development of others.
Antibody response and characteristics of antibodies in women immunized with three contraceptive vaccines inducing antibodies against human chorionic gonadotropin
Abstract
Data are presented on antibody titers generated in 88 women immunized with three formulations of antihuman chorionic gonadotropin (hCG) vaccine, namely, beta-hCG (formulation B); beta-hCG associated with alpha-subunit of ovine luteinizing hormone (LH) (formulation A) and beta-hCG + beta-ovine LH (formulation M), each linked to tetanus toxoid and cholera toxin chain B as carriers. Each formulation was tested at two dose levels (100 and 500 micrograms). All women without exception developed anti-hCG antibodies having hCG-binding capacity above 20 ng mL-1 (0.5 nM), a level considered to be the threshold for prevention of pregnancy. Formulations A and B gave relatively better immunogenic response in human subjects than M. In each case, the antibody response was reversible. The mean duration of response above 20 ng was 35 to 37 weeks for formulation A, 34 weeks for B, and 17 to 20 weeks for M. Antibodies induced by three formulations of the vaccine had high-affinity (Ka 10(9)-10(10)M-1) for binding with hCG. They were devoid of cross-reaction with human follicle-stimulating hormone and thyroid-stimulating hormone but, as expected, cross-reacted with human LH. Antibodies were competent to block the hCG induced ovarian hyperemia.
This is part of the "de-population agenda". I wonder who the lucky test subjects were.